STREPTOKINASE EFFICACY IN MYOCARDIAL INFARCTION MANAGEMENT: IS IT RELATED TO SERUM ANTISTREPTOKINASE ANTIBODY TITER

• Main Authors: H SHEMIRANI, A REZAEI, S MATIN KHAH, F OREYZI
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2000-06-01
• Series: Journal of Research in Medical Sciences
• Subjects: CORONARY ARTERY DISEASE, STREPTOKINASE, ANTISTREPTOKINASE, THROMBOLYTIC THERAPY
• Online Access: http://journals.mui.ac.ir/jrms/article/view/3516

Introduction. Antistreptokinase antibodies in sera of individuals with previous streptococcal infection might theoretically influence the thrombolytic activity of streptokinase. Streptokinase as the only thrombolytic drug is used in MI management in Iran. Since, the prevalence of streptococcal infections are higher in Iranian population, it seems that high level of antibodies in sera of patients would decrease the thrombolytic effect of Streptokinase.
 Methods. Antistreptokinase antibodies were measured by Home Made EL/SA method before streptokinase administration in 126 patients with MI who were admitted to Noor hospital (affiliated to Isfahan University of Medical Sciences and Health Services). The effect of drug with regard to ECG changes in following days were studied and compared.
 Results. In seventy patients of 126 (13.5 percent), the drug was ineffective and the antibody level was high. While in 25 patients with effective response to drug (no appearing of Q wave), 3 patients have a high level of antibody against streptokinase.
 Discussion. It seems that high level of serum antistreptokinase antibody titer has no significant interaction with thrombolytic activity of streptokinase in management of MI. However, most accurate study is required to test this hypothesis.